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Behavior of subclinical 
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involvement of the hPT axis, hPa 
axis, and Wnt/β-catenin Pathway
Jin-Fang Ge*†, Ya-Yun Xu†, Gan Qin, Jiang-Qun Cheng and Fei-Hu Chen*
Anhui Key Laboratory of Bioactivity of Natural Products, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China
Metabolic disease subclinical hypothyroidism (SCH) is closely associated with depres-
sion-like behavior both in human and animal studies, and our previous studies have 
identified the antidepressant effect of resveratrol (RES) in stressed rat model. The aim 
of this study was to investigate whether RES would manifest an antidepressant effect in 
SCH rat model and explore the possible mechanism. A SCH rat model was induced by 
hemi-thyroid electrocauterization, after which the model rats in the RES and LT4 groups 
received a daily intragastric injection of RES at the dose of 15 mg/kg or LT4 at the dose 
of 60 μg/kg for 16 days. The rats’ plasma concentrations of thyroid hormones were 
measured. Behavioral performance and hypothalamic–pituitary–adrenal (HPA) activity 
were evaluated. The protein expression levels of the Wnt/β-catenin in the hippocampus 
were detected by western blot. The results showed that RES treatment downregulated 
the elevated plasma thyroid-stimulating hormone concentration and the hypothalamic 
mRNA expression of thyrotropin-releasing hormone in the SCH rats. RES-treated rats 
showed increased rearing frequency and distance in the open-field test, increased 
sucrose preference in the sucrose preference test, and decreased immobility in the 
forced swimming test compared with SCH rats. The ratio of the adrenal gland weight 
to body weight, the plasma corticosterone levels, and the hypothalamic corticotrophin- 
releasing hormone mRNA expression were reduced in the RES-treated rats. Moreover, 
RES treatment upregulated the relative ratio of phosphorylated-GSK3β (p-GSK3β)/
GSK3β and protein levels of p-GSK3β, cyclin D1, and c-myc, while downregulating 
the relative ratio of phosphorylated-β-catenin (p-β-catenin)/β-catenin and expression of 
GSK3β in the hippocampus. These findings suggest that RES exerts anxiolytic- and 
antidepressant-like effect in SCH rats by downregulating hyperactivity of the HPA axis 
and regulating both the HPT axis and the Wnt/β-catenin pathway.
Keywords: depression, hypothalamus–pituitary–adrenal axis, hypothalamic–pituitary–thyroid axis, resveratrol, 
subclinical hypothyroidism, Wnt/β-catenin pathway
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inTrODUcTiOn
Imbalances in thyroid hormone homeostasis are associated 
with both functional and structural brain alterations, resulting 
in neurobehavioral alterations, including depression (1, 2). 
Subclinical hypothyroidism (SCH) is defined as an elevated 
plasma thyroid-stimulating hormone (TSH) level associated 
with normal total or free thyroxine (fT4) and triiodothyronine 
(T3) levels. Although the hypometabolism symptoms, including 
fatigue, weakness, and cold intolerance, are dormant and non-
specific in SCH patients, increasing evidence suggests that SCH 
is associated with neuropsychiatric disorders such as cognitive 
dysfunction (2) and depression (3, 4). Depression is observed 
more frequently among individuals with SCH than those with 
overt hypothyroidism (3), and SCH patients exhibit a twofold 
higher prevalence of depressive-like symptoms than healthy 
individuals (5). In our previous study, SCH induced depression-
like behavior in rats accompanied by subtle hyperactivity of the 
hypothalamus–pituitary–adrenal (HPA) axis (6). Clinical stud-
ies have demonstrated that treatment with levothyroxine (LT4) 
improves mood and normalizes the elevated relative cerebral 
glucose metabolism in several brain areas of depression patients 
(7, 8). However, the correct dosage of LT4 remains elusive. 
Moreover, the unpredictable clinical effects of the currently 
available antidepressants, including poor efficacy and adverse 
reactions, make the development of new drugs to alleviate 
depression in SCH patients an urgent clinical need.
Resveratrol (trans-3,5,4′-trihydroxy-trans-stilbene, RES), a 
polyphenol component found mainly in grape and Polygonum 
cuspidatum, possesses multiple biological and pharmacological 
activities, including metabolism regulation (9) and antioxidant 
effects (10). Recently, our results (11), together with find-
ings from other studies (12–15), have demonstrated that RES 
alleviates depression-like behavior in a rat model of chronic 
unpredicted mild stress (CUMS) through its antioxidant effects 
and by ameliorating hyperactivity of the HPA axis. In addition, 
the monoaminergic system and the molecular markers related to 
depression were also altered by RES treatment (16). However, it 
remains unknown whether RES can alleviate the depression-like 
symptoms in SCH, which is complicated with the balance of both 
the hypothalamic–pituitary–thyroid (HPT) axis and the HPA 
axis. Clinic studies showed that RES was well tolerated with the 
dose ranging from 200 mg (17) to 1000 mg (18) daily. According 
to the formula for dose translation based on body surface area 
(BSA), the corresponding dose in rats should range from 18 to 
90 mg/kg. With regard to animal research, it has been reported 
that RES (20, 40, and 80 mg/kg) could significantly decreased the 
immobility time of mice in the despair tests (19). Consistently, 
results of our previous study also demonstrated that RES (15 mg/
kg/day × 7 day) could significantly alleviate the depression-like 
behavior of CUMS rat (11). Thus, the dose of 15 mg/kg/day was 
chosen in this study.
Multiple approaches have been adopted to evaluate the anti-
depressant potential of compounds in animal models, includ-
ing behavioral tests and biochemical/neurochemical assays. 
In rodents, spontaneous motor activity and anxiety are often 
analyzed in terms of exploratory behavior, especially during 
exposure to an open field (20). And the clinical symptoms/
signs of depression such as anhedonia (incapability to perform 
rewarded behaviors) and helplessness are usually measured 
using the sucrose preference test (SPT) and the forced swim-
ming test (FST), respectively (13). In this study, these behavior 
tasks were used, and the activity of the HPA axis was also 
detected.
Several studies in recent years have implicated the canoni-
cal Wnt signaling pathway in mood disorders such as bipolar 
disorder (21) and major depression (22). Activation of the 
canonical Wnt pathway leads to the inhibition of GSK-3β, allow-
ing β-catenin to be stabilized in the cytosol and translocated to 
the nucleus, where it activates the transcription of target genes 
(23). Mutant mice with a heterozygous GSK-3β deletion showed 
decreased evidence of depression in the FST (23), and infusion 
of L803-mts, a selective GSK-3 inhibitor, also decreased immo-
bility in the same test (24). Additionally, upregulated β-catenin 
has been used as a marker for antidepressive-like effects (24). 
Furthermore, thyroid hormone exerts a negative effect on the 
canonical Wnt signaling pathway, as demonstrated in a previ-
ous study (25). Thyroid hormone stimulates cell proliferation, 
represses the expression of key members of the Wnt signaling 
pathway, and suppresses β-catenin levels (25). Therefore, the 
Wnt/β-catenin pathway may participate in SCH-associated 
depression.
In this study, in order to explore the potential antidepressant-
like effect of RES in the SCH rats and the possible mechanisms, 
behavior performance were evaluated using a series of behavioral 
tasks [open-field test (OFT), SPT, and FST]. Moreover, the activi-
ties of the HPA axis, the HPT axis, and the canonical Wnt pathway 
were assessed biochemically.
eXPeriMenTal PrOceDUres
Drugs
Resveratrol was purchased from Sigma Chemical Co. (St. Louis, 
MO, USA). LT4 was purchased from Berlin-Chemie AG (Berlin, 
Germany). Both drugs were dissolved in an aqueous solution of 
0.5% sodium carboxymethyl cellulose to be a mixed suspension. 
Control and untreated model rats received a daily intragastric 
injection of 0.5% sodium carboxymethyl cellulose.
animals
Male, 2-month-old Sprague-Dawley rats were purchased 
from the Anhui Experimental Animal Center of China. They 
were housed three to four per cage (43  cm length  ×  31  cm 
width × 19 cm height) with access to food and water ad libitum 
and were maintained under a 12:12-h light/dark cycle. The light 
onset is at 8 o’clock. The ambient temperature was maintained at 
21–22°C with 50–60% relative humidity. The rats were handled 
for 5  min daily over 7  days before drug administration. All 
experimental procedures in this study were approved by the 
Animal Care and Use Committee at the University of Science and 
Technology of China, which complies with the National Institute 
of Health Guide for the Care and Use of Laboratory Animals 
(NIH publication No. 85-23, revised 1985).
FigUre 1 | schedule of the experimental design. RES, resveratrol; LT4, 
levothyroxine; T3, triiodothyronine; fT4, free thyroxine; CRH, corticotrophin-
releasing hormone; TRH, thyrotropin-releasing hormone.
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animal Model of sch
The SCH rat model was established via hemi-electrocauterization, 
according to the procedures in our previous study (6). In brief, 33 
rats underwent hemi-thyroid electrocauterization to establish the 
SCH model, and 8 sham rats underwent the same operation, but 
the thyroid tissues were exposed without electrocauterization. 
The SCH model was evaluated 2  weeks later, and the success 
rate of SCH modeling was 75.8% (25/33), according to the 
criterion that the plasma TSH concentration was higher than 
the 97.5 percentile of the sham group accompanied by a plasma 
fT4 level between the 2.5 and 97.5 percentile of the sham group. 
Consequently, 24 successful SCH rats were randomly divided into 
3 groups with 8 rats in each group: an untreated model group, a 
RES treatment group (15 mg/kg/day + model) and an LT4 treat-
ment group (60 μg/kg/day + model). The rats in the RES and LT4 
groups received a daily intragastric injection of RES and LT4 at 
the corresponding dose for 16 days, respectively, and the rats in 
the sham and untreated model groups simultaneously received 
the same injection with 0.5% sodium carboxymethyl cellulose. To 
prevent hypocalcemia resulting from destruction of the parathy-
roid glands by electrocauterization, the rats were provided with 
0.1% (w/v) calcium lactate in their drinking water after surgery.
Behavioral Tests
Behavioral tests were performed in a soundproof room with a 
neutral environment in the order listed in Figure 1. Briefly, SPT 
was carried out on day (D) 34, OFT on D 35, and FST on D 36 
and D 37. All of the tests were carried out between 0900 and 
1430 hours, with matching between the groups. The observers 
were blind to the treatment. The behavioral performance was 
monitored and recorded by a digital camera above the apparatus 
interfaced to a computer running the ANY-maze video imaging 
software (Stoelting Co., Wood Dale, IL, USA).
Sucrose Preference Test
After a 12-h period of food and water deprivation, the animals 
were individually housed in a cage (28  cm length  ×  17  cm 
width ×  14.5  cm height) during the test and given two bottles 
(capacity: 250 ml) containing either water or a 2% sucrose solution. 
Six hours later, the volumes of water and sucrose consumed were 
measured. The percentage of the total liquid ingested was sucrose 
solution that was used as a measure of the sensitivity to reward.
Open-Field Test
The open-field apparatus consisted of a black square arena 
(100 cm × 100 cm), with a 30-cm-high wall. The floor was marked 
with a grid dividing it into 16 equally sized squares. During a 
5-min observation period, the rat was placed at one corner of the 
apparatus facing the wall. After the 5-min test, rats were returned 
to their home cages, and the open field was cleaned with 75% ethyl 
alcohol and permitted to dry between tests. The total distance; 
average velocity; the distance, frequency, and duration in the 
center; and the frequencies of rearing, grooming, and defecation 
were recorded.
Forced Swimming Test
The behavioral cylinder was 60 cm high and 25 cm in diameter, 
maintained at 24–25°C, and filled with 30 cm of water, so that 
rats could not support themselves by touching the bottom with 
their paws. The FST paradigm includes two sections: an initial 
15-min pretest followed by a 5-min test 24 h later. Rats were con-
sidered immobile when they did not make any active movements. 
Struggling was indicated when the rats made active movements 
with their forepaws in and out of the water along the side of the 
swim chamber. Swimming was indicated when the rats made 
active swimming or circular movements.
Measurement of Plasma concentrations 
of Thyroid hormones and corticosterone
Two weeks after the operation, blood samples (approximately 
1 ml) were collected from the angular vein to test whether the 
SCH rat model was successfully established. Twenty-four hours 
after the last behavioral test, the rats were deeply anesthetized 
with chloral hydrate, and blood was taken from the abdominal 
aorta. Plasma concentrations of TSH and corticosterone were 
measured using ELISA kits (TSH: Cusabio Biotech. Co., Ltd., 
Wuhan, Hubei, China; corticosterone: Enzo Life Sciences, Inc., 
USA), according to the manufacturer’s instructions, and fT4 and 
T3 were measured with radioimmunoassay kits (North Institute 
of Biological Technology, Beijing, China), with the apparatus used 
in the assay that came from University of Science and Technology 
of China Zonkia (AnHui Ustc ZonKia Scientific Instruments Co., 
Ltd., Anhui China).
The ratio of the adrenal gland Weight to 
Body Weight
The adrenal glands of each side were removed and weighed 
immediately postmortem. The ratio of the average of both glands 
weight to body weight was measured.
rna isolation and real Time Pcr
After blood collection, eight rats in each group were sacrificed 
by decapitation to collect the hypothalamus. The hypothalamus 
TaBle 1 | concentrations of plasma total triiodothyronine (T3), free thyroxine (fT4), thyroid-stimulating hormone (Tsh) in sham (n = 8), model (n = 8), 
res (n = 8), and lT4 (n = 8) before and after treatment.
group n T3 (nmol/l) fT4 (ρmol/l) Tsh (miU/l)
Before after Before after Before after
Sham 8 0.78 ± 0.03 0.72 ± 0.04 9.45 ± 0.34 5.78 ± 0.51 0.45 ± 0.06 0.46 ± 0.05
Model 8 0.75 ± 0.04 0.74 ± 0.05 9.44 ± 0.41 6.36 ± 0.40 2.28 ± 0.34** 1.31 ± 0.03**
RES 8 0.78 ± 0.05 0.66 ± 0.16 9.36 ± 0.49 6.84 ± 0.53 2.58 ± 0.29** 0.55 ± 0.09#
LT4 8 0.79 ± 0.02 0.81 ± 0.05 8.91 ± 0.25 15.67 ± 0.85**,## 2.68 ± 0.28** 0.09 ± 0.01##
The data were presented as mean ± SEM.
**P < 0.01 compared with sham group.
#P < 0.05 and ##P < 0.01 compared with model group.
RES, resveratrol; LT4, levothyroxine.
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was rapidly dissected and frozen quickly in liquid nitrogen 
before storage at −80°C. Total RNA was extracted using the 
TRIzol (Invitrogen, Carlsbad, CA, USA) method. cDNA was 
synthesized using reverse transcriptase (Promega, WI, USA). 
Q-PCR was performed using the SYBR Green PCR Kit (Applied 
Biosystems, USA) and an ABI Prism 7000 Sequence Detector 
system in a 25-μl total reaction volume for 40 cycles (15  s at 
95°C and 60 s at 62°C). The primers used in our study were as 
follows: rat β-actin 5′-TTGCTGACAGGATGCAGAA-3′ and 
5′-ACCAATCCACACAGAGTACTT-3′; thyrotropin-releasing 
hormone (TRH) 5′-AGCTCAGCATCTTGGAAAGC-3′ and 
5′-CCAGCAGCAACCAAGTC-3′; and corticotrophin-releasing 
hormone (CRH) 5′-CAGAACAACAGTGCGGGCTCA-3′ and 
5′-AAGGCAGACAGGGCGACAGAG-3′. The relative amount 
of each target gene was calculated using the 2−ΔΔCt method.
Western Blot assays
The hippocampus was homogenized in radioimmunoprecipita-
tion assay (RIPA) buffer (50 mM Tris–HCl at pH 7.4, 0.1% SDS, 
1% NP-40, 0.25% sodium deoxycholate, 150  mM NaCl, 1  mM 
EDTA, 1 mM EGTA, and 1 mM Na3VO4). Before homogeniza-
tion, a protease inhibitor cocktail (Roche, IN, USA) and the 
phosphatase inhibitor PhosSTOP (Roche, IN, USA) were added. 
Protein quantitation was conducted using a Lowry Protein Assay 
Kit (Meiji Biotech Co., Ltd., Shanghai, China). The same quantity 
(approximately 50 μg) of protein from each animal was loaded 
and separated by 15% SDS-PAGE and then transferred onto a 
polyvinylidene difluoride membrane (Amersham Biosciences, 
UK). The membrane was blocked with 5% skim milk for 1  h, 
incubated with antibodies targeting GSK3β, p-GSK3β (Ser9), 
β-catenin, p-β-catenin (1:1000; Cell Signaling Technology, USA), 
cyclin D1, c-myc (1:1000; ImmunoWay, Newark, DE, USA), or 
β-actin (1:1000; Bioworld Technology, Inc., USA) at 4°C overnight, 
and then incubated with a horseradish peroxidase-conjugated 
secondary antibody (1:10,000) at 37°C for 1  h. The blots were 
developed with the Easy Enhanced Chemiluminescence Western 
Blot Kit (Pierce Biotechnology, Rockford, IL, USA). The protein 
bands were scanned and analyzed using Image J software (NIH).
statistical analyses
All statistical analyses were performed using SPSS (Statistical 
Package for the Social Sciences) version 12.0.1 (SPSS Inc., 
Chicago, IL, USA). The data are expressed as the means ± SEM, 
and P < 0.05 was considered statistically significant. The distribu-
tion of the data was determined by the Kolmogorov–Smirnov test. 
Between-group effects on body weight, TSH, fT4, and T3 were 
analyzed by repeated measures ANOVA with group and days as 
the factors. Statistical analyses of the between-group effects of 
RES on behavioral performance, the ratio of the adrenal gland 
weight to body weight, plasma corticosterone, the hypothalamic 
mRNA expression of CRH and TRH, and the hippocampal protein 
expression of GSK3β, p-GSK3β (Ser9), β-catenin, p-β-catenin, 
cyclin D1, and c-myc were carried out using ANOVA followed 
by LSD post hoc tests. Correlation analysis was performed using 
a Pearson correlation test.
resUlTs
res administration Decreased the 
elevated Plasma Tsh and the 
hypothalamic Trh mrna in sch rats
The repeated measures ANOVA revealed that both the treat-
ment [F(5,140) = 11.975, P < 0.001] and time [F(3,28) = 76.925, 
P <  0.001] had a significant effect on the TSH levels, with no 
significant interaction [F(5,140) =  0.583, P =  0.614]. When it 
comes to the T3 levels, the results showed that neither the time 
[F(5,140) = 0.555, P = 0.461] nor the treatment [F(3,28) = 0.673, 
P =  0.574] had a significant effect, with no significant inter-
action [F(5,140)  =  0.452, P  =  0.718]. Moreover, repeated 
measures ANOVA revealed a significant interaction between 
the treatments and weeks in body weight [F(15,140) =  23.989, 
P < 0.001]. The individual factor treatment also had a significant 
effect [F(5,140) = 26.113, P < 0.001], but the factor time did not 
[F(3,28) = 2.509, P = 0.122].
As shown in Table 1, before the treatment, SCH rats in the 
untreated model, RES and LT4 groups showed elevated plasma 
TSH level [F(3,28) = 13.263, P < 0.01; LSD: sham vs. untreated 
model: P  =  0.002, sham vs. RES: P  <  0.001, sham vs. LT4: 
P < 0.001] with normal plasma fT4 [F(3,28) = 0.737, P = 0.539; 
LSD: sham vs. untreated model: P  =  0.378, sham vs. RES: 
P = 0.689, sham vs. LT4: P = 0.876] and T3 [F(3,28) = 1.505, 
P = 0.235; LSD: sham vs. untreated model: P = 0.778, sham vs. 
RES: P = 0.701, sham vs. LT4: P = 0.423] concentrations com-
pared with the sham ones. After 16 days of treatment, both RES 
FigUre 2 | effect of res on hypothalamic Trh mrna expression in 
the sch rats. The mRNA expression of TRH in the hypothalamus is 
illustrated. The data are presented as the means ± SEM, with n = 8 for each 
group. *P < 0.05 and **P < 0.01 compared to the sham group. #P < 0.05 
and ##P < 0.01 compared to the untreated model group. RES, resveratrol; 
TRH, thyrotropin-releasing hormone; SCH, subclinical hypothyroidism.
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and LT4 decreased the elevated TSH level of untreated model 
rats [F(3,28) = 11.269, P < 0.01; LSD: RES vs. untreated model: 
P = 0.028, LT4 vs. untreated model: P < 0.01]. No significant dif-
ference was found between sham rats and RES- or LT4-treated 
rats (LSD: RES vs. sham: P = 0.213, LT4 vs. untreated model: 
P = 0.711). Consistent with this result, the hypothalamic mRNA 
expression of TRH was inhibited by treatment with RES or LT4 
[Figure 2, F(3,16) = 6.668, P < 0.001; LSD: RES vs. untreated 
model: P = 0.050, LT4 vs. untreated model: P = 0.01, RES vs. 
sham: P = 0.221, LT4 vs. untreated model: P = 0.611]. No signifi-
cant difference was observed between the plasma T3 concentra-
tions of the groups [Table 1, F(3,28) = 2.563, P = 0.458]. LT4, 
but not RES, increased the plasma fT4 concentrations compared 
to sham or untreated model rats [Table  1, F(3, 28) =  60.583, 
P < 0.01; LSD: RES vs. sham: P = 0.202; LT4 vs. sham: P < 0.001; 
RES vs. untreated model: P = 0.340, LT4 vs. untreated model: 
P < 0.001].
res administration Did not reverse the 
Decreased Bodyweight in the sch rats
Figure  3A shows the effect of RES on the body weight and 
behaviors of the SCH rats. Repeated measures ANOVA revealed 
a significant interaction between the treatments and weeks in 
body weight [F(15,140)  =  3.707, P  <  0.01]. The individual 
factor weeks also had a significant effect [F(5,140) = 165.550, 
P < 0.01], but the factor treatments did not [F(3,28) = 1.633, 
P = 0.198]. A significant difference in body weight was noticed 
in week 5 in the sham rats compared to the untreated model rats 
[F(3,28) =  3.179, P =  0.035; LSD: sham vs. untreated model: 
P = 0.027, RES vs. untreated model: P = 0.785, LT4 vs. untreated 
model: P = 0.745, RES vs. sham: P = 0.015, LT4 vs. untreated 
model: P =  0.052]. However, no change in body weight was 
observed during the experimental period in the untreated 
model rats compared to the RES- or LT4-treated rats, indicating 
that neither drug had an effect on the body weights of untreated 
model rats.
res administration alleviated the  
anxiety- and Depressive-like Behavior 
in the sch rats
The sucrose preference of the untreated model rats was remark-
ably lower than that of the sham group. Both the RES and LT4 
groups showed an elevated sucrose preference index compared to 
the untreated model rats [Figure 3B, F(3,28) = 6.387, P = 0.001; 
LSD: RES vs. untreated model: P =  0.002, LT4 vs. untreated 
model: P =  0.035, RES vs. sham: P =  0.849, LT4 vs. untreated 
model: P =  0.224], indicating an anti-anhedonia effect of RES 
and LT4.
In the OFT (Figures 3C–G), the untreated model group trave-
led over a shorter total distance [F(3,28) = 9.983, P < 0.01; LSD: 
RES vs. untreated model: P =  0.002, LT4 vs. untreated model: 
P =  0.018, RES vs. sham: P =  0.022, LT4 vs. untreated model: 
P = 0.004] and at a lower velocity [F(3,28) = 9.987, P < 0.01; LSD: 
RES vs. untreated model: P =  0.002, LT4 vs. untreated model: 
P =  0.017, RES vs. sham: P =  0.023, LT4 vs. untreated model: 
P = 0.004] than the sham group, and these measures were amelio-
rated by the RES and LT4 treatments. These results indicate that 
both drug treatments improved the SCH rats’ locomotor activity. 
Moreover, a decreased number of rearing was observed in the 
untreated model rats, and this behavior was increased in the SCH 
rats treated with RES or LT4 [F(3,28) = 13.560, P < 0.01; LSD: 
RES vs. untreated model: P =  0.001, LT4 vs. untreated model: 
P =  0.008, RES vs. sham: P =  0.006, LT4 vs. untreated model: 
P  =  0.001], indicating that both drug treatments improved 
exploratory behavior. As the total distance and frequency of rear-
ing are also used as measures of anxiety (26), these data revealed 
that the drug treatments may have decreased the high anxiety 
levels in the untreated model rats. However, no differences in the 
number of grooming behaviors and defecations were observed 
between the SCH rats with and without RES treatment.
In the FST (Figures 3H–J), the untreated model rats spent a 
longer time immobile [F(3,28) = 4.792, P < 0.01; LSD: RES vs. 
untreated model: P = 0.014, LT4 vs. untreated model: P = 0.004, 
RES vs. sham: P = 0.351, LT4 vs. untreated model: P = 0.646] and 
less time swimming [F(3,28) = 3.557, P = 0.023; LSD: RES vs. 
untreated model: P = 0.014, LT4 vs. untreated model: P = 0.004, 
RES vs. sham: P = 0.351, LT4 vs. untreated model: P = 0.646], and 
these changes were reversed by RES or LT4 treatment, indicating 
that RES alleviated the despairing behavior in the SCH rats.
res administration Decreased the ratio 
of the adrenal gland Weight to Body 
Weight, Plasma corticosterone, and 
hypothalamic crh mrna in sch rats
Although the ratio of the adrenal gland weight to body 
weight was  significantly increased in the untreated model rats 
(Figure  4A), both RES and LT4 significantly decreased the 
ratio compared to the sham group [F(3,28) = 22.777, P < 0.001; 
LSD: sham vs. untreated model: P <  0.001, RES vs. untreated 
model: P < 0.001, LT4 vs. untreated model: P < 0.001, RES vs. 
sham: P = 0.011, LT4 vs. untreated model: P = 0.604]. After the 
hemi-thyroid electrocauterization, plasma corticosterone in the 
FigUre 3 | effect of res on the body weight and behaviors of the sch rats. The body weight (a), sucrose preference (B), and performance in the OFT (c–g) 
and FST (h–J) were observed. The data are presented as the means ± SEM, with n = 8 for each group. *P < 0.05 and **P < 0.01 compared to the sham group. 
#P < 0.05 and ##P < 0.01 compared to the untreated model group. RES, resveratrol; SCH, subclinical hypothyroidism; OFT, open-field test; FST, forced swimming test.
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FigUre 4 | effects of res on the ratio of the adrenal gland weight to body weight, the plasma corticosterone, and the expression of crh mrna in 
the hypothalamus in sch rats. The ratio of the adrenal gland weight to body weight (a), the plasma corticosterone (B), and the expression of CRH mRNA in the 
hypothalamus (c) are shown. The data are presented as the means ± SEM, with n = 8 for each group. *P < 0.05 and **P < 0.01 compared to the sham group. 
#P < 0.05 and ##P < 0.01 compared to the untreated model group. RES = resveratrol, SCH = subclinical hypothyroidism, CRH = corticotrophin-releasing hormone.
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untreated model rats increased significantly, while treatment with 
either RES or LT4 decreased the elevated corticosterone levels 
[Figure 4B, F(3,28) = 19.066, P < 0.01]. In line with this result, 
the elevated hypothalamic CRH mRNA expression noted in the 
untreated model rats was decreased by treatment with either RES 
or LT4 [Figure 4C, F(3,28) = 9.468, P < 0.01].
res administration Decreased activation 
of the canonical Wnt Pathway in the 
hippocampus of sch rats
Figure  5 shows the protein expression levels of GSK-3β, 
p-GSK-3β (Ser9), β-catenin, p-β-catenin, cyclin D1, and 
c-myc in rat hippocampi. Compared with those of the sham 
group, a lower protein expression of p-GSK-3β [Figure  5A, 
F(3,28) = 23.969, P < 0.01] and relative ratio of p-GSK-3β/GSK-
3β [F(3,28) = 21.902, P < 0.01] and a higher protein expression 
of GSK-3β [F(3,28) =  23.673, P <  0.01] were observed in the 
hippocampus of the untreated model rats, which was reversed by 
the RES or LT4 treatment.
As shown in Figure  5B, a higher protein expression of 
 p-β-catenin [Figure  5B, F(3,28) =  11.322, P <  0.01] and rela-
tive ratio of p-β-catenin/β-catenin [Figure 5B, F(3,28) = 11.641, 
P <  0.01] were observed in the hippocampus of the untreated 
model rats. Conversely, the protein expression of β-catenin 
[Figure  5B, F(3,28) =  7.44, P =  0.002] was lower than that of 
the sham group. These changes were reversed by treatment with 
RES or LT4.
Consistently, hippocampal protein levels of cyclin D1 
[Figure 5C, F(3,28) = 7.457, P < 0.01] and c-myc [F(3,28) = 8.922, 
P <  0.01] were lower in the untreated model rats than in the 
sham ones, but these changes were improved by treatment with 
RES or LT4. Altogether, these results indicate that the canonical 
Wnt pathway was activated in the hippocampus of the untreated 
model rats and that activation was ameliorated by the RES 
treatment.
Results of Pearson correlation analysis showed that the expres-
sions of p-β-catenin/β-catenin were both negatively correlated to 
cyclin D1 (r = −0.566, P = 0.004) or c-myc (r = −0.565, P = 0.004).
DiscUssiOn
In this study, we explored the antidepressant effects of RES in 
SCH rats. The results showed that RES treatment could alleviate 
anxiety- and depression-like behavior in SCH rats, as indicated 
by their increased rearing frequency and moving distance in the 
OFT, their elevated sucrose preference index, and their decreased 
immobility in the FST. Moreover, RES treatment improved the 
imbalance of HPA and HPT axes observed in the SCH rats. 
Furthermore, RES treatment downregulated activation of the 
canonical Wnt pathway in the hippocampus of SCH rats.
Subclinical hypothyroidism is a common thyroid dysfunc-
tion that occurs in 4–20% of the adult population. The risk of 
SCH progressing to overt hypothyroidism is approximately 7% 
(27), and both overt and SCH are associated with an increase in 
FigUre 5 | effects of res on the activation of the canonical Wnt pathway in the hippocampi of sch rats. Representative blots and the quantitative 
analysis of GSK3β and p-GSK3β (a), β-catenin and p-β-catenin (B), cyclin D1 and c-myc (c) are presented. The data are presented as the means ± SEM, with 
n = 8 for each group. *P < 0.05 and **P < 0.01 compared to the sham group. #P < 0.05 and ##P < 0.01 compared to the untreated model group. RES, resveratrol; 
SCH, subclinical hypothyroidism.
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the number and severity of depressive-like symptoms (28,  29). 
LT4 is the routine clinical treatment for SCH. In this study, our 
results show that the imbalance of the HPT axis in SCH rats was 
improved by the treatment of LT4, as indicated by the decrease of 
both the plasma TSH and the hypothalamic TRH mRNA expres-
sion. However, the possibility of overtreatment is one of  the 
adverse effects of LT4 treatment, and the risk ranges from 14 to 
21% (30). Consistently, with a dose parallel to the routine dose 
used clinically, LT4-treated SCH rats showed significantly higher 
plasma fT4 concentration than the sham rats in our study.
The adverse side effects of LT4, including the hyperthyrox-
inemia, make the development of new therapeutic drugs to 
treat SCH necessary. Recently, a new concept of antidepressant 
mechanisms of action has been proposed based on the findings 
that antidepressants showed immediate antioxidant effects in the 
treatment of major depressive disorder (31). Increasing evidence 
from animal studies suggests that treatment with antioxidants 
can reduce oxidative stress and alleviate depressive-like behaviors 
(32). RES is a polyphenol antioxidant that has versatile biological 
and pharmacological activities, including neuroprotective effects 
(19, 33). Our results reveal that treatment with RES decreases 
both the plasma TSH concentration and the hypothalamic TRH 
mRNA expression in SCH rats without increasing the plasma 
concentration of fT4. Although the specific mechanism remains 
unknown, this effect might be partly attributable to the capacity 
of RES to regulate TSH secretion by manipulating the levels of 
SIRT1 (34).
The OFT provides simultaneous measures of locomotion, 
exploration, and anxiety (26). In this study, the untreated model 
rats showed a decrease in the total distance traveled and the 
frequency of rearing in the OFT, which was increased in the SCH 
rats treated with RES, indicating that RES treatment improved 
the decreased locomotor activity and exploration in the untreated 
model rats. Moreover, the decreased total distance traveled and 
frequency of rearing indicated a higher level of anxiety in the 
untreated model rats, which may also have been reduced by 
the treatment with RES and LT4. The SPT is commonly used to 
assess anhedonia, which is a prominent symptom of depression 
in rodents. Immobility in the FST is taken as an index of despair 
behavior, which is another prominent symptom of depression. 
In this study, the SCH rats showed decreased sucrose preference 
index in the SPT and increased immobility in the FST, indicating 
a depression-like behavior in SCH rats, which was consistent with 
the findings in our previous study (6). Moreover, Detke et al. found 
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that antidepressant drugs, which inhibit norepinephrine reuptake 
(desipramine or reboxetine) effectively, reduced immobility and 
selectively increased climbing behavior without affecting swim-
ming, whereas the selective serotonin reuptake inhibitor (SSRI), 
which works through the serotonin system, reduced immobility 
and selectively increased swimming, without affecting climbing. 
In this study, our results showed that both RES and LT4 reduced 
immobility behaviors in the model rats (35). Thus, it is possible 
that RES might have an analogous therapeutic effect with the 
SSRIs in certain types of depression. Further studies are in need 
to verify the reliability of this hypothesis.
Treatment of thyroid dysfunction could reduce the psychiatric 
symptoms of depression in general (36), and clinical studies 
have shown an improvement in depressive-like symptoms after 
treatment with LT4 in SCH patients (37, 38). Thus, LT4 was 
selected as a positive control in this study. The results showed the 
expected antidepressant effect of LT4 on the SCH rats. Similarly, 
RES-treated rats showed an increased sucrose preference index 
and decreased immobility in the FST. These results indicate that 
treatment with RES also alleviated the depression-like behavior 
of the SCH rats.
Hyperactivity of the HPA axis is one of the most potent fac-
tors that trigger depression episodes (39), and abnormalities 
in HPA axis function are also well documented in rats with 
hypothyroidism (6). Similarly, the SCH rats displayed elevated 
adrenal mass, plasma corticosterone, and hypothalamic CRH 
mRNA expression. However, these changes were ameliorated by 
treatment with RES. Although RES reportedly stimulated cortisol 
biosynthesis and secretion in H295R adrenocortical cells in vitro 
(40), our results and other reports indicate that RES reduced the 
serum corticosterone concentration in stressed rats (11, 14) and 
unstressed mice (41). This discrepancy about the effect of RES on 
the HPA axis may be partly ascribed to the different experimental 
techniques and methods in the different studies.
Studies on human brains have evaluated the levels or activ-
ity of total GSK-3β protein in the prefrontal cortex in mood 
disorders, including depression (22, 42), and increasing evi-
dence suggests that inhibition of GSK-3β might contribute to 
antidepressant activity (43). Consistent with the report that the 
enzymatic activity of GSK-3β was increased in depressed sui-
cide victims (42), lower pGSK-3β and pGSK-3β/GSK-3β levels 
in the hippocampus were found in the SCH rats, which could 
induce depression-like behavior in this study (6). However, the 
increased GSK-3β levels were improved by the treatment with 
RES. L803-mts, a known GSK-3β inhibitor (24), induced an 
anti-immobility effect in the FST. Moreover, a lower GSK-3β 
level expressed in heterozygotic GSK-3β+/− mice was associated 
with reduced immobility time in the FST (44). These results 
suggest a role for GSK-3β in the antidepressive-like effects of 
RES and highlight GSK-3β as a potential target in the treatment 
of SCH-associated depression.
β-catenin, a substrate of GSK-3β (45), has been implicated 
in brain development, cognitive activity, and dendritic growth 
(46). Phosphorylation of β-catenin by GSK-3β enhances the 
degradation of the protein, whereas phosphorylation of GSK-3β 
stabilizes β-catenin and promotes its accumulation in the cell 
cytoplasm. The unphosphorylated β-catenin can then migrate 
into the nucleus, where it associates with transcription factors 
to stimulate gene expression (47). β-catenin protein levels were 
lower in the postmortem prefrontal cortices of depressed sub-
jects compared to non-depressed controls (22), and β-catenin 
levels in the hippocampus can serve as a marker for antidepres-
sant behavior (48). Consistent with these results, the protein 
levels of p-β-catenin and p-β-catenin/β-catenin were upregu-
lated in the hippocampus of the SCH rats, indicating β-catenin 
degradation. Together with these reports, the findings from this 
study reinforce the clinical observation that depressed subjects 
display a high GSK-3β activation state and low β-catenin levels 
(22).
Recent studies have demonstrated that cyclin D1 and c-myc, 
critical genes involved in cell proliferation and differentiation, 
were important target genes of the Wnt signaling pathway. 
Overexpression of cyclin D1 and c-myc is highly associated 
with the accumulation of β-catenin and mutational defects of 
the Wnt signaling pathway (49). In this study, protein levels 
of cyclin D1 and c-myc were decreased due to the increased 
β-catenin protein levels in the SCH rats, which was improved by 
RES treatment, further confirming the therapeutic effect of RES. 
Several recent studies have focused on the relationship between 
β-catenin and cyclin D1 or c-myc. For instance, a strong cor-
relation was reported between β-catenin deregulation and cyclin 
D1 expression in primary colorectal tumors (50). Brabletz et al. 
(51) also reported a tight correlation between nuclear β-catenin 
accumulation and c-myc expression in colorectal adenomas. 
In this study, the results of Pearson’s correlation test suggested 
a significant positive association between the expression of 
p-β-catenin/β-catenin and cyclin D1 or c-myc. Based on our 
findings, the abnormal expression of β-catenin and its associ-
ated dysfunction of cyclin D1 and c-myc may play a key role in 
SCH-associated depression.
In this study, we first observed that RES alleviates depression-
like behavior in SCH rats, which may be due to the regulation of 
HPA and HPT axes and the activity of the Wnt/β-catenin pathway 
in the hippocampus. Consistent with reports that RES does not 
cause adverse effects (15, 52), our results confirm that RES does 
not cause hyperthyroxinemia, which is a potential therapeutic 
advantage over LT4 treatment. However, this study presented 
several limitations. First, RES was administered only in a single 
dose. Thus, its dose relationship and long-term side-effects should 
be determined using different doses in future studies. Second, 
considering our previous finding that RES could alleviate the 
depression-like behavior of CUMS rats, together with the reports 
that RES treatment does not cause adverse effects (15, 52), we 
did not administer RES to the sham rats, which might make it 
subtly difficult to interpret many of the results. Third, although 
LT4 treatment was selected as a positive control in this study, the 
effect of RES on the depression-like behavior of the SCH rats was 
not compared with that of conventional antidepressant medica-
tions, such as fluoxetine.
In conclusion, our results demonstrate that RES improved 
anxiety- and depression-like behavior in SCH rats. This effect 
may be due, at least in part, to regulation of the HPA and HPT 
axes and the Wnt/β-catenin pathway in the hippocampus. 
Compared with the possible adverse effects of LT4 treatment, 
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including cardiovascular events and symptoms associated with 
excess thyroid hormone, such as nervousness and palpitations 
(53), the credible efficacy with high safety margins (54, 55) of 
RES make it a promising candidate for the treatment of SCH-
associated depression.
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